D-0738-2026 Class III Ongoing
FDA drug recall D-0738-2026 was initiated by Ascend Laboratories, LLC on Jul 16, 2026 and is designated Class III. Reason for recall: Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability The recall status is ongoing. Affected quantity: 924 cartons x 12 x 6 x 10 (in blister pack).
Recall details
- Product Type
- Drugs
- Report Date
- Aug 5, 2026
- Initiation Date
- Jul 16, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 924 cartons x 12 x 6 x 10 (in blister pack)
Product description
Dabigatran Etexilate Capsules, 75 mg, 60-count (6x10)blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-68.
Reason for recall
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
Distribution pattern
USA Nationwide
Code information
Lot: 25141585, Exp. April 30, 2027.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0738-2026
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026